Monoclonal Antibodies to the Rescue

Starting off 2022 on a good note, another potential treatment for celiac disease is going into clinical trials! Janssen, the pharmaceutical arm of Johnson and Johnson, has launched a Phase 1b clinical trial for a new potential monoclonal antibody celiac disease treatment called guselkumab.

Guselkumab is the first potential celiac disease treatment in clinical trials that is already FDA approved for use in other conditions. Guselkumab is currently approved for treating various forms of psoriasis, and is in ongoing clinical trials for a number of other conditions, including Crohn’s disease and psoriatic arthritis.

Thanks to Beyond Celiac for great reporting on the study. You can read more here and get info if you're interested in participating.

Hosted on Acast. See acast.com/privacy for more information.